Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus PITOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus PITOCIN.
OXYTOCIN 10 USP UNITS IN DEXTROSE 5% vs PITOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.
Oxytocin receptor agonist; stimulates uterine smooth muscle contractions and myoepithelial cell contraction in the mammary gland.
IV infusion: 0.5-2 mU/min, increased by 1-2 mU/min every 30-60 min until desired uterine activity, then reduce; max 20 mU/min.
IV infusion: 0.5-2 mU/min, increase by 1-2 mU/min every 15-60 minutes until contractions are established; maximum 20 mU/min.
None Documented
None Documented
Terminal half-life: 1-6 minutes (IV); clinical effect ceases rapidly after infusion stops due to rapid clearance.
Terminal elimination half-life is 3-5 minutes (plasma) with a terminal half-life of 1-6 minutes for exogenously administered oxytocin; clinical effects persist 20-30 minutes due to receptor binding.
Renal: >99% as unchanged drug; <1% hepatic metabolism and biliary excretion.
Primarily renal: 90-95% of the dose is excreted in urine as intact peptide and metabolites; <1% excreted in feces via bile.
Category C
Category C
Oxytocic
Oxytocic